Q2 delivered 29% revenue growth and a 35% adjusted EBITA margin, driven by strong performance across all regions and key products. Full-year 2026 guidance was raised for both revenue and margin, with pipeline progress and new launches supporting long-term growth.Based on Swedish Orphan Biovitrum AB…
Q2 delivered 29% revenue growth and a 35% adjusted EBITA margin, driven by strong performance across all regions and key products. Full-year 2026 guidance was raised for both revenue and margin, with pipeline progress and new launches supporting long-term growth.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.